Oncology drug health technology assessment recommendations: Canadian versus UK experiences
Isabelle Chabot,1 Angela Rocchi2 1EvAccess, Vaudreuil, QC, Canada; 2Athena Research, Burlington, ON, Canada Background: Canada has two health technology assessment (HTA) agencies responsible for oncology drug funding recommendations: the Institut National d’Excellence en Santé e...
Saved in:
Main Authors: | Chabot I (Author), Rocchi A (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
by: Rocchi A, et al.
Published: (2015) -
The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health
by: Chakrapani Balijepalli, et al.
Published: (2024) -
Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada
by: Rawson NSB, et al.
Published: (2024) -
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
by: Oriol Solà-Morales, et al.
Published: (2019) -
Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review
by: Balijepalli C, et al.
Published: (2020)